Tatar Bengü, Acar Ayse, Adar Pelın, Kose Sukran
Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Izmir Tepecik Education and Research Hospital, Turkey.
Clin Exp Hepatol. 2020 Feb;6(1):55-59. doi: 10.5114/ceh.2020.93058. Epub 2020 Feb 17.
The quantitative hepatitis B surface antigen (qHBsAg) level indicates the amount of transcriptional activity of covalently closed circular DNA (cccDNA) and integrated DNA in hepatocytes which plays a role in development of chronic hepatitis B (CHB) and may help decide whether the treatment is necessary or not. The aim of this study is to evaluate the association between serum qHBsAg levels and viral replication and stage of liver fibrosis in treatment-naive CHB patients and to determine the role of qHBsAg levels in predicting when liver biopsy is necessary.
967 patients were included in the study. Because of refusal of liver biopsy the study was conducted on 123 patients. The association between qHBsAg levels with HBV DNA, a-fetoprotein, fibrosis stage and histology activity index was evaluated.
Of the patients, mean age was 48 ±11.2 years and 56.1% were male. We found that patients with HBV DNA ≥ 2000 IU/ml had a higher qHBsAg titer in comparison with HBV DNA < 2000 IU/ml. However, there was no relationship between qHBsAg titer and liver necroinflammation or fibrosis stage.
Monitoring of qHBsAg together with HBV DNA may be helpful in CHB management. However, qHBsAg level does not provide knowledge about the timing of biopsy or the decision of CHB treatment.
定量乙肝表面抗原（qHBsAg）水平可指示肝细胞中共价闭合环状DNA（cccDNA）和整合DNA的转录活性量，这在慢性乙型肝炎（CHB）的发展中起作用，并可能有助于决定是否需要治疗。本研究的目的是评估初治CHB患者血清qHBsAg水平与病毒复制及肝纤维化分期之间的关联，并确定qHBsAg水平在预测何时需要肝活检中的作用。
967例患者纳入本研究。由于123例患者拒绝肝活检，故对其进行研究。评估qHBsAg水平与HBV DNA、甲胎蛋白、纤维化分期及组织学活动指数之间的关联。
患者的平均年龄为48±11.2岁，56.1%为男性。我们发现，与HBV DNA<2000 IU/ml的患者相比，HBV DNA≥2000 IU/ml的患者qHBsAg滴度更高。然而，qHBsAg滴度与肝脏坏死炎症或纤维化分期之间没有关系。
qHBsAg与HBV DNA一起监测可能有助于CHB的管理。然而，qHBsAg水平并不能提供有关活检时机或CHB治疗决策的信息。
